Selank: what is known about its effects, research and approval status?
Clinical review pending
Selank is being studied as an anti-anxiety peptide. Small Russian studies offer limited evidence; this article covers proposed mechanisms, how it compares with Semax and its described US regulatory status.
Whether selank reliably eases anxiety cannot be said yet. Small Russian studies do report anti-anxiety effects, but their results have not been independently confirmed. The data are not enough to establish efficacy by Western regulatory standards. Ideas about how selank works come mainly from animal and laboratory studies.
What is selank?
Selank, sometimes called TP-7, is a synthetic peptide, meaning a short chain of amino acids. It is made up of seven amino acids and is a stabilized version of the naturally occurring peptide tuftsin. Selank was developed by Russian research institutes, and in Russia it is approved as an anti-anxiety medicine.
Outside Russia, wellness vendors and sellers of so-called “research peptides” market selank for anxiety and to sharpen concentration. In the United States it is not an approved medicine.
How does selank work?
Researchers are looking at several processes in the brain as possible explanations for a calming effect: selank might influence the enkephalin and GABA systems as well as serotonin metabolism. It might also change levels of BDNF, a signaling molecule involved in the growth of nerve cells.
These assumptions rest mainly on animal and laboratory studies. They explain how selank might work, but they do not show any benefit in humans.
Is selank FDA-approved?
No. The US Food and Drug Administration (FDA) has not approved selank. In Russia it is approved as an anxiolytic, that is, an anti-anxiety medicine. In the United States, sellers offer it as a “research chemical.”
A separate question from approval status is whether pharmacies may use selank to prepare individualized medicines. In the United States this practice is called compounding. For September 2026, the source material describes selank as not listed for compounding; it also does not count selank among the peptides that received a favorable assessment at the FDA’s 2026 compounding advisory meetings. No definitive legal conclusion can be drawn from this.
What does the research show?
A few small Russian studies in humans report anti-anxiety effects. They include a comparison with a benzodiazepine and a study [1] suggesting that selank might reduce the side effects of benzodiazepines. These studies carry limited weight. As a rule, they are:
- small,
- limited to a single country,
- often carried out by institutions involved in developing the drug,
- published in Russian,
- not independently repeated and confirmed.
An analytical review [2] notes that peptides of this kind have not completed clinical testing to Western regulatory standards. By those standards, the results so far do not count as proof of efficacy.
How do selank and Semax differ?
Selank and Semax each consist of seven amino acids. Both synthetic peptides were developed by Russian research institutes. They are, however, derived from different natural molecules and are approved in Russia for different uses. Their proposed mechanisms also differ.
| Feature | Selank | Semax |
|---|---|---|
| Derived from | Tuftsin, a natural peptide that influences the immune system; selank is a stabilized version | A fragment of the hormone ACTH |
| Approved in Russia for | Use as an anti-anxiety medicine | Stroke and cognitive and neurological disorders |
| Proposed mechanism | Influences the enkephalin and GABA systems in the brain and serotonin metabolism | Increases growth signals for nerve cells such as BDNF and NGF 3 |
| FDA approval status | Not FDA-approved | Not FDA-approved |
| US compounding policy as of October 30, 2026 | Selank is not included in the six-peptide HHS policy | The draft, nonbinding HHS policy describes conditional enforcement discretion for single-ingredient Semax free base for intranasal use. This is not FDA approval or final 503A-list inclusion. HHS policy Federal Register |
The mechanisms described are based mostly on animal and laboratory studies. For neither peptide has it been shown that these mechanisms produce a benefit in humans. Compounding policy is a separate question. The October HHS document describes a favorable advisory recommendation but does not make it FDA approval. Its Semax scope is restricted to intranasal free base and single-ingredient products, subject to a patient-specific prescription, qualifying manufacturer and certificate of analysis, identity and quality testing, labeling, reporting, and other applicable requirements. It does not cover injectable Semax, peptide blends, or Selank. A clinician and pharmacist should check the current requirements for a specific preparation. HHS policy Federal Register
The human studies have similar limitations. For both peptides there are small, mostly Russian studies, often from institutions involved in development. Independent confirmation is missing. The analytical review [2] also points out that no clinical testing to Western regulatory standards has been completed. With these data, it is not possible to establish that either peptide works, or to decide which one works better.
Frequently asked questions
Is selank FDA-approved?
No. The FDA has not approved selank in the United States for any indication. In Russia it is approved as an anti-anxiety medicine. There it has been studied in people with generalized anxiety disorder and neurasthenia 5.
As of the described status in September 2026, the FDA lists selank acetate in a table of substances that were nominated for inclusion but whose nomination was later withdrawn 6. On that basis, selank acetate is not on the “503A bulks list,” a list of bulk substances that pharmacies can use to prepare medicines. Whether US pharmacies may use selank for such preparations cannot be settled from this list entry alone.
Is it legal to buy selank in the US in 2026?
The compounding information does not settle whether buying it is legal. For September 2026, the source material classifies selank as not eligible for compounding under Section 503A. That alone does not amount to a full legal assessment of a purchase.
For selank products sold online without a prescription, there is no evidence of FDA testing for quality, purity or concentration. Buying from online sellers therefore raises product quality risks on top of the regulatory questions.
Selank is structurally derived from tuftsin. It is studied mainly as an anti-anxiety agent, and also for possible effects on the immune system 7. Semax is based on the ACTH fragment 4-7 3. Research on it focuses mainly on neuroprotective (nerve-cell-protecting) and nootropic effects, which concern cognitive function. One of its proposed effects is increased production of BDNF.
Both peptides were developed by Russian research institutes and are given intranasally, that is, through the nose. They differ in their proposed mechanisms, in the effects mainly studied and in their approved uses in Russia. They are not interchangeable.
What do published studies on selank show?
Russian clinical studies report anti-anxiety effects similar to those of the benzodiazepine medazepam 5. In another study, researchers reported fewer side effects from phenazepam when selank was given alongside it. This included less sedation, meaning a weaker dulling and drowsiness-inducing effect 1. The English-language abstracts do not put numbers on the differences compared with the benzodiazepines. So the size of the observed effects cannot be read from them.
Studies of gene expression in rats, that is, of gene activity, point to one possible mechanism. According to these, selank might act on the GABA system allosterically: the effect would be mediated through a site on the receptor other than its primary binding site 8. Animal findings like these do not show benefit in humans. Confirmation of the clinical results by Western randomized controlled trials (RCTs) is still lacking.
What route of administration is mainly used in selank research?
Research mainly studies selank given intranasally, that is, through the nose. In one mouse study, selank reduced anxiety-like behavior in the more anxious mouse strain after both intranasal and intraperitoneal administration. The latter means the substance was given into the abdominal cavity 9.
Different routes of administration produced different changes at receptors in the brain. After injection, binding to GABA receptors in the frontal cortex increased; after nasal administration, binding to NMDA receptors increased. How these differences translate to use in humans is only partly understood.
What is the FDA’s Category 2 list of peptides?
The FDA’s Category 2 covers bulk drug substances that the agency considers to pose significant safety risks. It is part of the process under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding of individualized medicines in pharmacies.
As of the described status in September 2026, Category 2 [10] contains only cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use, that is, for use in the uterus.
In April 2026, the FDA removed a group of peptides from Category 2 after the nominators withdrew their nominations. Selank acetate had already been removed earlier for the same reason. It is listed in the table of substances with withdrawn nominations 6.
Are peptides legal again after the April 2026 removals from Category 2?
Removal from Category 2 after a nomination is withdrawn does not itself confer FDA approval or final 503A-list inclusion. The April 2026 procedural change therefore should not be read as a general legalization. Conversely, absence from Category 1 alone does not settle every current compounding question: the October 30 HHS draft policy describes a separate, conditional enforcement approach for six named peptides. Selank is not one of them. HHS policy Federal Register
The source material described Selank as not eligible for compounding under Section 503A in September 2026. The October HHS policy does not extend its limited scope to Selank. Neither statement provides a complete legal assessment of a particular product or purchase; the compound, formulation, jurisdiction, and applicable requirements matter.
Will selank be available again from compounding pharmacies?
No date can be given for Selank availability from compounding pharmacies. Addition to an applicable list or another relevant regulatory development would require a specific current assessment. The October 2026 HHS policy does not include Selank, and its provisions for Semax cannot be transferred to Selank. HHS policy Federal Register
As of the described status in September 2026, selank was not on the agenda of the July 2026 advisory committee meeting [11]. No public timeline for a decision had been announced. Changes are announced in the FDA’s updates on its procedures for bulk drug substances.
Sources
- Sources: a Russian clinical study of selank (Medvedev et al., Zhurnal Nevrologii i Psikhiatrii, 2015, DOI: 10.17116/jnevro20151156133-40 1 ) and an analytical review of research peptides (Esposito et al., Drug Testing and Analysis, 2020, DOI: 10.1002/dta.2717 2 ), indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product. Original source Original source